Three-day regimen of oseltamivir for postexposure prophylaxis of influenza in wards

N. Ishiguro; R. Oyamada; Y. Nasuhara; T. Yamada; T. Miyamoto; S. Imai; K. Akizawa; T. Fukumoto; S. Iwasaki; H. Iijima; K. Ono

doi:10.1016/j.jhin.2016.05.012

Three-day regimen of oseltamivir for postexposure prophylaxis of influenza in wards

N. Ishiguro, R. Oyamada, Y. Nasuhara, T. Yamada, T. Miyamoto, S. Imai, K. Akizawa, T. Fukumoto, S. Iwasaki, H. Iijima, K. Ono

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Inpatients who had been in close contact with patients with influenza were given oseltamivir [75 mg capsules once daily for adults or 2 mg/kg (maximum of 75 mg) once daily for children] for three days as postexposure prophylaxis (PEP). The index patients with influenza were prescribed a neuraminidase inhibitor and were discharged immediately or transferred to isolation rooms. The protective efficacy of oseltamivir for three days was 93% overall [95% confidence interval (CI) 53–99%; P=0.023] and 94% for influenza A (95% CI 61–99%; P=0.017), which is comparable to that of seven- to 10-day regimens of oseltamivir as PEP.

Original language	English
Pages (from-to)	150-153
Number of pages	4
Journal	Journal of Hospital Infection
Volume	94
Issue number	2
DOIs	https://doi.org/10.1016/j.jhin.2016.05.012
Publication status	Published - 2016 Oct 1
Externally published	Yes

Keywords

Influenza
Oseltamivir
Postexposure prophylaxis

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jhin.2016.05.012

Cite this

@article{0a026b26cc0e4c679e21541c083a2e90,

title = "Three-day regimen of oseltamivir for postexposure prophylaxis of influenza in wards",

abstract = "Inpatients who had been in close contact with patients with influenza were given oseltamivir [75 mg capsules once daily for adults or 2 mg/kg (maximum of 75 mg) once daily for children] for three days as postexposure prophylaxis (PEP). The index patients with influenza were prescribed a neuraminidase inhibitor and were discharged immediately or transferred to isolation rooms. The protective efficacy of oseltamivir for three days was 93% overall [95% confidence interval (CI) 53–99%; P=0.023] and 94% for influenza A (95% CI 61–99%; P=0.017), which is comparable to that of seven- to 10-day regimens of oseltamivir as PEP.",

keywords = "Influenza, Oseltamivir, Postexposure prophylaxis",

author = "N. Ishiguro and R. Oyamada and Y. Nasuhara and T. Yamada and T. Miyamoto and S. Imai and K. Akizawa and T. Fukumoto and S. Iwasaki and H. Iijima and K. Ono",

note = "Publisher Copyright: {\textcopyright} 2016 The Healthcare Infection Society",

year = "2016",

month = oct,

day = "1",

doi = "10.1016/j.jhin.2016.05.012",

language = "English",

volume = "94",

pages = "150--153",

journal = "Journal of Hospital Infection",

issn = "0195-6701",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Three-day regimen of oseltamivir for postexposure prophylaxis of influenza in wards

AU - Ishiguro, N.

AU - Oyamada, R.

AU - Nasuhara, Y.

AU - Yamada, T.

AU - Miyamoto, T.

AU - Imai, S.

AU - Akizawa, K.

AU - Fukumoto, T.

AU - Iwasaki, S.

AU - Iijima, H.

AU - Ono, K.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Inpatients who had been in close contact with patients with influenza were given oseltamivir [75 mg capsules once daily for adults or 2 mg/kg (maximum of 75 mg) once daily for children] for three days as postexposure prophylaxis (PEP). The index patients with influenza were prescribed a neuraminidase inhibitor and were discharged immediately or transferred to isolation rooms. The protective efficacy of oseltamivir for three days was 93% overall [95% confidence interval (CI) 53–99%; P=0.023] and 94% for influenza A (95% CI 61–99%; P=0.017), which is comparable to that of seven- to 10-day regimens of oseltamivir as PEP.

AB - Inpatients who had been in close contact with patients with influenza were given oseltamivir [75 mg capsules once daily for adults or 2 mg/kg (maximum of 75 mg) once daily for children] for three days as postexposure prophylaxis (PEP). The index patients with influenza were prescribed a neuraminidase inhibitor and were discharged immediately or transferred to isolation rooms. The protective efficacy of oseltamivir for three days was 93% overall [95% confidence interval (CI) 53–99%; P=0.023] and 94% for influenza A (95% CI 61–99%; P=0.017), which is comparable to that of seven- to 10-day regimens of oseltamivir as PEP.

KW - Influenza

KW - Oseltamivir

KW - Postexposure prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=84995581927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995581927&partnerID=8YFLogxK

U2 - 10.1016/j.jhin.2016.05.012

DO - 10.1016/j.jhin.2016.05.012

M3 - Article

C2 - 27346624

AN - SCOPUS:84995581927

SN - 0195-6701

VL - 94

SP - 150

EP - 153

JO - Journal of Hospital Infection

JF - Journal of Hospital Infection

IS - 2

ER -

Three-day regimen of oseltamivir for postexposure prophylaxis of influenza in wards

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this